Prostate Cancer and Immunotherapy

Friday
October 8, 2021, 3:05 pm -
3:40 pm
Changing the outlook for metastatic prostate cancer

Watch On Demand

Session Description

As the second most common male cancer in the world, roughly 1.3 million people receive a prostate cancer diagnosis each year. In its early stages, prostate cancer is highly treatable, but when advanced, effective treatments are limited. That’s where cancer immunotherapy offers new hope. There are already two FDA-approved immunotherapies—a therapeutic cancer vaccine and a checkpoint inhibitor—and many more promising treatments in clinical trials. Join Dr. Ana Aparicio of the University of Texas MD Anderson Cancer Center to discuss exciting scientific and clinical research. She’ll answer your questions about biomarkers and genomic sequencing, combination therapies, clinical trials, side effects, and more.

Speaker(s)

Ana Aparicio, M.D.

The University of Texas MD Anderson Cancer Center

Ana Aparicio is an associate professor at MD Anderson Cancer Center’s Department of Genitourinary Medical Oncology, who specializes in the treatment of advanced prostate cancer. Her clinical and translational research focuses on the development of novel therapies for a subset of aggressive prostate cancer. Through a series of prospective clinical trials and parallel studies in preclinical models, she defined a molecular signature for this subset and has shown that it predicts treatment resistance. This work serves as the foundation for a much-needed biologically-based, clinically-relevant molecular classification of prostate cancer that will increase the efficiency of clinical and translational research, permit effective and individualized treatment strategies for the lethal variants, and spare patients unnecessary treatments.

On-Demand Now Available

We are excited to announce that videos from our 2021 Cancer Research Institute (CRI) Virtual Immunotherapy Patient Summit are now available to view on demand.

The on-demand videos can be found on each session page from the agenda.